Web20 set 2024 · Purpose: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab … WebAtezolizumab + Bevacizumab for Hepatocellular Carcinoma. Hepatocellular carcinoma is a common cancer worldwide and a leading cause of cancer-related death. 1 Although early-stage disease may be ...
Tremelimumab and Durvalumab Improves OS in Advanced …
WebMore recently, the HIMALAYA trial demonstrated the superiority of durvalumab-tremelimumab (STRIDE regimen) over sorafenib, establishing a new first-line option. In … WebAccording to the positive results of HIMALAYA trial , cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor tremelimumab plus programmed death ligand-1 (PD-L1) inhibitor durvalumab is recommended as an alternative first-line therapy to Atezo-Bev by the BCLC group, while durvalumab monotherapy is approved in the first-line setting by the … scariest movies out now
HIMALAYA Phase III trial exploratory results support the benefit …
Web4 lug 2024 · This trial is registered with ClinicalTrials.gov, NCT03755791. Findings Analyses at data cut-off (March 8, 2024) included the first 837 patients randomly assigned … Web13 giu 2024 · Other ongoing phase III trials investigating pembrolizumab-based regimens in HCC that may inform treatment selection in various settings include KEYNOTE-937 of pembrolizumab as adjuvant therapy (NCT03867084), and LEAP-012 of the combination of pembrolizumab and lenvatinib, in combination with transarterial chemoembolization for … Web15 ott 2024 · The frontline combination of tremelimumab and durvalumab (Imfinzi) achieved a statistically significant and clinically meaningful overall survival (OS) benefit compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment, meeting the … scariest movies on youtube